Stockscreener 앱 받기
0.4286
5.24%
-0.0211
전일 마감가:
$0.4497
열려 있는:
$0.44
하루 거래량:
339.25K
Relative Volume:
0.16
시가총액:
$17.74M
수익:
$656.60K
순이익/손실:
$-16.79M
주가수익비율:
-0.399
EPS:
-1.0743
순현금흐름:
$-11.12M
1주 성능:
-9.18%
1개월 성능:
+15.39%
6개월 성능:
+10.86%
1년 성능:
-58.63%
1일 변동 폭
$0.4211
$0.4599
1주일 범위
$0.4211
$0.4806
52주 변동 폭
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
명칭
Scienture Holdings Inc
전화
(800) 261 0281
주소
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, MEDS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.432 | 19.37M | 656.60K | -16.79M | -11.12M | -1.0743 |
HITI
High Tide Inc
|
2.475 | 215.28M | 486.49M | -33.29M | 10.86M | -0.3627 |
PETS
Petmed Express Inc
|
1.74 | 38.15M | 179.02M | -57.29M | -33.01M | -2.7487 |
POM
Pomdoctor Ltd Adr
|
0.9556 | 7.61M | 0 | 0 | 0 | 0.00 |
MEDS
Trxade Health Inc
|
1.321 | 4.44M | 7.15M | 4.03M | -11.33M | -5.40 |
Scienture Holdings Inc 주식(SCNX)의 최신 뉴스
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report: Shares Fall 0.49% in the Latest SessionEarnings Growth Forecast - vinanet.vn
Scienture Q2 Revenue Surges 510% Sequentially on Commercial Product Growth - Minichart
Scienture Q2 Revenue Reaches $343,639 as Net Loss Narrows 58% - Quiver Quantitative
Scienture stock jumps 21% on REZENOPY commercial launch - scanx.trade
Scienture (SCNX) Q1 2026 Results: Profit Per Share Clears Its Benchmark in the Latest Session; Closing Reaction: Shares Rise 3.76% in Latest TradingOperating Income Trends - vinanet.vn
$Scienture Holdings (SCNX.US)$ LMAO. They give us a buy rating, but wont let us buy. - Moomoo
SCNX Q1 2026 Earnings: Loss Narrower Than Expected, Shares Rise 2.18%Earnings Analysis - vinanet.vn
Scienture Holdings 2Q Loss/Shr 7c >SCNX - moomoo.com
Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses - Quiver Quantitative
SCNX Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
$Scienture Holdings (SCNX.US)$ - Moomoo
Scienture Holdings: Q2 Earnings Snapshot - marketscreener.com
Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026 - Stock Titan
Scienture Holdings, Inc. Q2 2026: Revenue $343.64K, EPS $(0.07) — 10-Q Summary - TradingView
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Yahoo Finance
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com Nigeria
Scienture launches naloxone nasal spray for opioid overdose - Investing.com
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - marketscreener.com
Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg - marketscreener.com
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Yahoo Finance
Scienture Holdings Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Scienture Holdings Inc (SCNX) Stock News Today - TradingKey
Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 64.35%New Analyst Coverage - vinanet.vn
Scienture Holdings (SCNX) Holds Near $0.38 as Trading Range Tightens Between $0.36 Support and $0.40 ResistanceComposite Profile - dars.gov.et
Scienture Holdings, Inc. (NASDAQ: SCNX) Stock Price, News & Analysis - Kalkine
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, But Shares Slide 4%Guidance Upgrade Report - vinanet.vn
Scienture Holdings, Inc. Revenue Breakdown – NASDAQ:SCNX - TradingView
Scienture Holdings Inc (SCNX) Cash Flow - TradingKey
Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
When Will Scienture Holdings, Inc. (NASDAQ:SCNX) Become Profitable? - simplywall.st
Scienture Holdings Inc (SCNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enterprise value to EBITDA forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Strong EPS SurpriseAnalyst Earnings Estimate - vinanet.vn
Scienture Holdings Inc (SCNX) Balance Sheet - TradingKey
Scienture Holdings Inc (SCNX) Income Statement - TradingKey
Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SCNX|Scienture Holdings Inc|Price:0.370|Chg%:+0.001 - TradingKey
Scienture Holdings Inc (SCNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SCNX|Scienture Holdings Inc|Price:0.372|Chg%:+0.003 - TradingKey
SCNX|Scienture Holdings Inc|Price:0.357|Chg%:-0.012 - TradingKey
Scienture Holdings Inc (SCNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Scienture Holdings (SCNX) Faces Modest Decline, Testing Key Support at $0.37Dark Pool Sentiment - vinanet.vn
DataMEDS AI Intends to Target GLP-1 Muscle Loss and Long COVID - Stock Titan
SCNX SEC FilingsScienture Holdings, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Scienture completes manufacturing for naloxone spray launch By Investing.com - Investing.com Nigeria
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionConsensus Beat Rate - dars.gov.et
Scienture Holdings stock jumps over 20% pre-market: Here's why - MSN
Scienture Holdings Company Profile & Introduction - Moomoo
Scienture Holdings Inc (SCNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.58%
5.11%
자본화:
|
볼륨(24시간):